How Much Does IVIG Treatment Cost?

Updated on July 18, 2026 | Written by Alec Pow
This article was researched using 4 sources. See our methodology and corrections policy.

IVIG treatment commonly costs $5,000 to $15,000 or more per infusion before insurance adjustments, although high-dose treatment can exceed $20,000 to $40,000 per course. Ongoing therapy may cost $60,000 to $200,000+ per year, with heavier patients, high-dose regimens, hospital outpatient treatment, and frequent maintenance schedules producing substantially higher totals.

The price is primarily driven by the number of grams prescribed. U.S. cash and billed prices are often quoted at approximately $100 to $350+ per gram, but the insurer’s allowed amount may be much lower than the provider’s original charge. Administration, nursing, supplies, laboratory work, premedications, and facility charges are added separately.

A patient’s actual responsibility may range from a modest copay to thousands of dollars in deductible and coinsurance. Coverage depends on the diagnosis, product, dose, prior authorization, medical or pharmacy benefit, treatment setting, network status, and annual out-of-pocket maximum.

Article Highlights

• IVIG is often priced at approximately $100 to $350+ (at $30 per hour, earning that amount would take about 0.4 to 1.5 full-time workdays, before taxes) per gram before insurance adjustments.
• A common adult infusion may cost $5,000 to $15,000+.
• A high-dose loading course may cost $20,000 to $40,000+.
• Ongoing therapy can cost $60,000 to $200,000+ per year.
• The main calculation is body weight multiplied by the prescribed dose in grams per kilogram.
• Hospital outpatient departments may cost more than physician offices, independent centers, or approved home infusion.
• Medicare coverage depends on the diagnosis, benefit category, site of care, and applicable coverage rules.

How Much Does IVIG Treatment Cost?

There is no single price for an IVIG infusion because two patients can receive very different numbers of grams. A smaller patient receiving antibody-replacement dosing may need only a fraction of the product required for a heavier patient receiving a high-dose immunomodulatory course.

IVIG cost category	Current planning range	What changes the amount
IVIG product	$100 to $350+ (about 0.4 to 1.5 full-time workdays at $30 per hour) per gram	Brand, payer contract, pharmacy, vial use, and treatment site
Common adult infusion	$5,000 to $15,000+	Weight, dose, product price, and administration fees
High-dose loading course	$20,000 to $40,000+	Total grams and number of administration days
Infusion administration	$500 to $2,000+	Nursing, facility, supplies, monitoring, and duration
Ongoing annual therapy	$60,000 to $200,000+	Maintenance dose, interval, weight, and site of care
High-dose annual treatment	$200,000 to $500,000+	Large doses, frequent courses, and expensive care settings

A published U.S. analysis involving chronic inflammatory demyelinating polyneuropathy, or CIDP, cited an average IVIG cost of approximately $9,720 per infusion and about $108,016 per year. These were study estimates rather than a universal current price, but they provide useful context for the scale of long-term treatment. The study is available through the National Library of Medicine.

The amount shown on a hospital bill should not be assumed to be the amount an insurer pays. Commercial insurers, Medicare, Medicaid programs, specialty pharmacies, and providers use contracted or regulated payment methods that can differ markedly from cash pricing.

How IVIG Pricing Is Calculated

The basic drug-cost formula is:

Patient weight in kilograms × prescribed dose in g/kg × price per gram

Administration and related medical charges are then added:

Drug cost + nursing and infusion services + facility fee + supplies + laboratory work + premedications

Consider a 70-kilogram adult receiving an IVIG dose of 1 g/kg:

• Patient weight: 70 kg
• Prescribed dose: 1 g/kg
• Total IVIG required: 70 grams
• Assumed product price: $150 (about 5 hours of work at $30 per hour) per gram

The IVIG product subtotal is $10,500. Adding $500 to $2,000 for administration, supplies, monitoring, and the treatment site produces an estimated total of $11,000 to $12,500.

If the same 70 grams are billed at $250 per gram, the drug subtotal becomes $17,500. This demonstrates why the contracted price per gram can matter almost as much as the prescribed dose.

Cost by Dose and Body Weight

The following examples show the IVIG product cost before administration fees for a 70-kilogram adult:

Prescribed regimen	Total IVIG	At $150 per gram	At $250 per gram
0.4 g/kg	28 grams	$4,200	$7,000
0.6 g/kg	42 grams	$6,300	$10,500
1 g/kg	70 grams	$10,500	$17,500
2 g/kg total course	140 grams	$21,000	$35,000

These examples are not dosing recommendations. The prescribing clinician selects the product, dose, interval, and infusion rate based on the diagnosis, approved labeling, patient response, medical history, and payer requirements.

A change in body weight can materially alter the cost. At a dose of 1 g/kg and an assumed price of $150 per gram, a 50-kilogram patient has a $7,500 product subtotal, while a 100-kilogram patient has a $15,000 product subtotal.

Loading Dose vs Maintenance Therapy

A loading course is an initial higher dose intended to begin treatment or produce a rapid therapeutic effect. The total amount may be divided over several consecutive days for tolerability and safe administration.

Those administration days should not be miscounted as separate complete treatment courses. A prescription for 2 g/kg divided over five days remains one 2 g/kg course, not five separate 2 g/kg treatments.

FDA prescribing information for Privigen lists primary-immunodeficiency dosing of 200 to 800 mg/kg every three to four weeks. Its adult CIDP regimen includes a loading dose of 2 g/kg divided over two to five consecutive days, followed by an individualized maintenance schedule. The current details appear in the FDA-approved Privigen prescribing information.

Gamunex-C labeling similarly allows a CIDP loading dose totaling 2 g/kg, divided over two to five consecutive days, with maintenance dosing afterward. Its primary-immunodeficiency schedule is commonly administered every three to four weeks. The exact regimen appears in the FDA-approved Gamunex-C label.

Some patients receive treatment at other intervals because diagnosis, response, side effects, or accepted off-label use may require an individualized plan. The article’s earlier assumption of four to eight complete IVIG treatments every month did not describe a typical maintenance schedule.

Drug Cost vs Infusion Charges

The immune globulin product is usually the largest line item, but an infusion bill can contain several additional charges:

• Pharmacy preparation and product handling
• Infusion nurse time
• IV catheter placement and supplies
• Infusion pump and tubing
• Premedications or hydration
• Laboratory testing
• Physician or specialist supervision
• Facility or hospital outpatient fee
• Monitoring during and after the infusion

A provider may bill the drug under separate units based on the product’s billing code and vial size. Unused product and billing rules can also influence the claim.

Request an estimate that separates:

• IVIG product and number of grams
• Administration charge
• Facility fee
• Laboratory and office-visit charges
• Premedications and hydration
• Expected insurer adjustment
• Estimated patient responsibility

A statement that merely says “infusion estimate: $12,000” does not show whether the amount is the provider’s charge, the insurer’s allowed amount, or the patient’s expected payment.

Hospital, Infusion Center, and Home Costs

Hospital outpatient department: Hospital-based care may have high facility and administration charges. It may still be medically appropriate for patients who need close monitoring, complex care, or immediate access to hospital support.

Independent infusion center: An independent center may have lower overhead and negotiated rates than a hospital outpatient department. Coverage depends on the insurer’s network and site-of-care policy.

Physician office: Some specialists provide IVIG in an office infusion suite. The office must have appropriate staff, supplies, monitoring, and emergency procedures.

Home infusion: Home treatment may reduce facility expenses and travel burden for carefully selected patients. It commonly involves a trained infusion nurse, pharmacy-supplied medication, equipment, and an insurer-approved care plan.

Home IVIG is not automatically 20% to 30% cheaper. The cost depends on drug contracts, nursing hours, delivery, supplies, treatment duration, insurance rules, and the patient’s clinical needs.

A site-of-care comparison should use the same dose and product. A hospital estimate for 80 grams cannot be fairly compared with a home estimate for 60 grams.

What Insurance May Cover

Private insurance may cover IVIG when the treatment meets the plan’s medical-necessity and clinical-policy requirements. Authorization commonly depends on:

• Confirmed diagnosis
• Prescribing specialist
• FDA-approved or plan-recognized indication
• Relevant laboratory or diagnostic findings
• Previous treatments and response
• Requested dose and frequency
• Approved IVIG brand
• In-network pharmacy and infusion provider
• Periodic documentation of continued benefit

The treatment may be processed under the medical benefit, pharmacy benefit, or a combination of both. That difference can change the deductible, coinsurance, specialty-pharmacy requirement, and prior-authorization process.

Do not rely on a statement that the insurer “covers IVIG.” Ask for written answers to these questions:

• Is the diagnosis covered?
• Is prior authorization approved?
• Which product and dose are authorized?
• Which provider and specialty pharmacy must be used?
• Does a site-of-care restriction apply?
• What is the remaining deductible?
• What coinsurance applies?
• How much remains before the out-of-pocket maximum?

Medicaid coverage and authorization rules differ by state. Private plans also use different formularies, clinical criteria, and network contracts. A universal promise that a payer covers a fixed percentage would be unreliable.

Medicare Home IVIG Coverage

Medicare coverage depends on the diagnosis, place of service, benefit category, medical necessity, and applicable Medicare rules. It should not be summarized as an automatic 80% payment for every IVIG patient.

Medicare Part B includes a specific home-IVIG benefit for qualifying patients with primary immune deficiency disease when the product and home treatment meet statutory and coverage requirements.

Effective January 1, 2024, Medicare established a permanent bundled payment for items and services required to administer qualifying IVIG in the home. The bundled payment can include nursing services and supplies such as tubing and an infusion set. CMS explains the current rules in its Medicare IVIG compliance guidance.

This home benefit is specifically associated with qualifying primary immune deficiency treatment. It does not mean every autoimmune, neurological, hematological, or off-label IVIG use qualifies under the same home-IVIG provision.

Patients with Original Medicare may also have a Medigap policy, employer retiree coverage, Medicaid, or another secondary payer that changes their remaining responsibility. Medicare Advantage plans must follow Medicare coverage requirements but may use network and authorization procedures.

Hidden Cost of Prior Authorization

Financial harm can arise before the first infusion when authorization, provider, product, and site-of-care requirements are not resolved.

Potential hidden costs include:

• Out-of-network pharmacy charges
• Denied treatment given before authorization
• Hospital facility fees
• Product changes requiring a new approval
• Repeat laboratory or specialist visits
• Missed work and transportation
• Delayed treatment while records are collected
• Reauthorization after several months

An authorization number does not always guarantee payment. The claim must still match the approved diagnosis, product, dose, provider, dates, and billing requirements.

Before treatment, ask the provider’s financial team for a benefits investigation and a written estimate. Confirm that both the infusion facility and the specialty pharmacy are in network.

IVIG vs SCIG Costs

IVIG is delivered through a vein. SCIG, or subcutaneous immunoglobulin, is delivered into tissue beneath the skin using a different product and administration method.

SCIG may be administered more frequently in smaller doses and can sometimes be self-administered after formal clinical training. That does not mean patients should self-administer IVIG or change routes without a new prescription and insurer approval.

SCIG may reduce facility and nursing expenses for some patients, but the drug cost, insurance coverage, training, pump, supplies, and dosing conversion must be considered. Research has not shown one route to be cheaper for every patient and health plan.

The choice depends on:

• Diagnosis and approved product
• Patient preference and dexterity
• Venous access
• Infusion reactions
• Frequency and volume
• Insurance coverage
• Clinical response

Ask the prescribing clinician whether a subcutaneous product is medically appropriate and ask the insurer for a side-by-side cost estimate.

Three IVIG Cost Scenarios

Lower-dose replacement therapy: A 60-kilogram patient receives 0.4 g/kg, or 24 grams. At $150 per gram, the product costs $3,600. Adding $900 in administration and related charges produces a total of $4,500.

Maintenance treatment: An 80-kilogram patient receives 1 g/kg, or 80 grams. At $175 per gram, the drug subtotal is $14,000. Administration and monitoring add $1,500, producing a total of $15,500 per treatment cycle.

High-dose loading course: A 70-kilogram patient receives a total of 2 g/kg, or 140 grams, divided over several days. At $200 per gram, the product subtotal is $28,000. Multiple administration days and related services add $3,000, producing an estimated course total of $31,000.

These examples illustrate cost calculations only. They do not establish an appropriate dose, frequency, product, or treatment plan for any patient.

Financial Assistance and Appeals

Patients facing a high deductible or coinsurance may investigate:

• Manufacturer copay programs
• Independent charitable foundations
• Hospital financial assistance
• Specialty-pharmacy support programs
• Provider payment plans
• Formal insurance appeals
• Employer HSA or FSA funds when eligible

Manufacturer copay assistance frequently excludes people enrolled in Medicare, Medicaid, TRICARE, and other government-funded insurance. Eligibility, funding, covered products, and annual limits can change.

Independent foundation assistance may open and close depending on available funding. Patients should verify that the organization is legitimate and does not require an improper payment to apply.

When a claim or authorization is denied, obtain:

• The denial letter and policy language
• The exact clinical criterion that was not met
• The physician’s supporting records
• Peer-reviewed evidence when relevant
• The appeal deadline
• Instructions for an expedited appeal when medically appropriate

Also ask whether copay assistance counts toward the plan deductible and out-of-pocket maximum. Some plan designs use accumulator or maximizer programs that change how third-party assistance is credited.

Safety and Monitoring Costs

IVIG products carry important medical risks and must be administered according to the prescribed product-specific instructions. FDA labeling for several IVIG products contains boxed warnings for thrombosis, renal dysfunction, and acute renal failure.

Other identified risks can include:

• Severe hypersensitivity
• Hemolysis
• Aseptic meningitis syndrome
• Transfusion-related acute lung injury
• Volume overload
• Headache, chills, fever, or nausea
• Blood-pressure changes and infusion reactions

These risks can affect the care setting and cost. A patient may require laboratory testing, hydration, a slower infusion, additional monitoring, or hospital-based administration.

There is no universal ideal infusion time such as four hours. The rate depends on the product, concentration, dose, weight, risk factors, previous tolerance, and clinician’s order. FDA-approved labels direct clinicians to begin at a product-specific rate and increase it only as tolerated.

Patients should not independently speed up, slow down, stop, restart, or extend an infusion. Symptoms during treatment should be reported immediately to the supervising professional.

What We Verified

• Checked current FDA-approved Privigen and Gamunex-C dosing information.
• Confirmed that primary-immunodeficiency and CIDP schedules use different doses and intervals.
• Verified that a multi-day loading course is one total prescribed dose divided across administration days.
• Confirmed Medicare’s permanent bundled home-IVIG items and services payment effective January 1, 2024.
• Removed blanket Medicare, Medicaid, and private-insurance coverage percentages.
• Removed the unsupported claim that 24-hour home infusion reduces the number of treatments required.
• Separated IVIG from self-administered subcutaneous immunoglobulin.

Related Medical Costs

Patients comparing infusion and diagnostic expenses can review the cost of an iron infusion, current blood test prices, and the cost of allergy testing.

Answers to Common Questions

How much does one IVIG infusion cost?

A common adult infusion may cost $5,000 to $15,000+ before insurance adjustments. High-dose courses can exceed $20,000 to $40,000.

Why is IVIG so expensive?

IVIG is manufactured from pooled human plasma and requires donor screening, collection, purification, testing, viral-reduction processes, quality control, cold-chain distribution, and specialized infusion services.

How is the IVIG dose calculated?

The dose is commonly based on body weight in kilograms and a prescribed number of grams or milligrams per kilogram. The diagnosis and treatment goal determine the regimen.

Does insurance cover IVIG?

Many plans cover IVIG for qualifying indications, but prior authorization, clinical documentation, an approved product, an in-network provider, and site-of-care rules may apply.

Is home IVIG cheaper?

Home infusion can reduce facility expenses for some patients, but nursing, supplies, delivery, drug contracts, and insurance rules determine whether it is less expensive.

Can a patient administer IVIG without a nurse?

Patients should not independently administer or adjust IVIG unless a qualified clinical team has established a specific medically appropriate home plan. Self-administered SCIG is a separate route and treatment system.

What happens if IVIG is infused too quickly?

An excessive rate may increase the likelihood of infusion reactions. The infusion should follow the product-specific prescription and be adjusted only by the supervising clinical professional.